Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Checkpoint Therapeutics
AddedFeb 19, 2024
UpdatedJun 18, 2026
Checkpoint Therapeutics

Checkpoint Therapeutics

Public

Checkpoint Therapeutics: A clinical-stage biopharmaceutical company focused on cancer therapy development.

HQ
Waltham, MA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Checkpoint Therapeutics, founded with a core mission to develop innovative cancer therapies, is a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focuses on creating and advancing novel treatments that harness the body's immune system to combat cancer. Their product pipeline includes multiple candidates at various stages of development, targeting a range of cancer types. Checkpoint Therapeutics aims to address significant unmet medical needs in the oncology market.

Notable figures associated with Checkpoint Therapeutics include experienced leaders in biopharmaceuticals and oncology research. The company has attracted investment from reputable firms, bolstering its research and development efforts. Key achievements include successful participation in major investor conferences such as the H.C. Wainwright BioConnect Investor Conference and consistent financial performance updates. Checkpoint Therapeutics' impact is marked by its commitment to advancing cancer treatment options and contributing to the broader field of immuno-oncology.

Checkpoint Therapeutics - Similar Companies

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

OnCusp Therapeutics logo

OnCusp Therapeutics

oncusptx.com

Pheast Therapeutics logo

Pheast Therapeutics

pheast.com

CytomX Therapeutics logo

CytomX Therapeutics

cytomx.com

BioEclipse Therapeutics logo

BioEclipse Therapeutics

bioeclipse.com

GO Therapeutics logo

GO Therapeutics

gotherapeutics.com

Seneca Therapeutics logo

Seneca Therapeutics

NextCure logo

NextCure

nextcure.com

G1 Therapeutics logo

G1 Therapeutics

g1therapeutics.com

Ascenta Therapeutics logo

Ascenta Therapeutics

Cullinan Oncology logo

Cullinan Oncology

NextPoint Therapeutics logo

NextPoint Therapeutics

nextpointtx.com

Oncofactor logo

Oncofactor

oncofactor.com

PineTree Therapeutics logo

PineTree Therapeutics

pinetreetx.com

Parthenon Therapeutics logo

Parthenon Therapeutics

parthenontx.com

Checkpoint Therapeutics - Quick Facts

Who are Checkpoint Therapeutics' competitors?

Companies similar to Checkpoint Therapeutics include Immune-Onc Therapeutics, OnCusp Therapeutics, Pheast Therapeutics and CytomX Therapeutics.

When was Checkpoint Therapeutics founded?

Checkpoint Therapeutics was founded in 2014.

Where is Checkpoint Therapeutics' headquarters located?

Checkpoint Therapeutics' headquarters is located in Waltham, MA, US.

When was Checkpoint Therapeutics' last funding round?

Checkpoint Therapeutics' most recent funding round was for $10M (USD) in May 2023.

How much has Checkpoint Therapeutics raised to-date?

As of May 23, 2023, Checkpoint Therapeutics has raised a total of $10M (USD).

How many employees does Checkpoint Therapeutics have?

Checkpoint Therapeutics has 24 employees as of Feb 6, 2024.

Checkpoint Therapeutics - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Therapies
Tags
  • Financial
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 14 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research